News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major economic data or policy announcements were published in the past hour, leaving markets without fresh catalysts.
  • Equity futures showed little movement as investors awaited upcoming scheduled data and earnings.
  • Treasury yields were mostly unchanged amid light headline flow.
  • The dollar traded flat against major currencies in absence of new macro signals.
  • Oil and industrial metals held recent levels with no fresh supply or demand news.
  • Political and geopolitical calendars produced no unexpected developments, reducing near-term headline risk.

Latest Articles

Pulmonx to Participate in Upcoming Investor Conferences

Pulmonx to Participate in Upcoming Investor Conferences

Pulmonx Corporation, a Nasdaq-listed company specializing in minimally invasive treatments for severe lung disease, will have its management team participate in two major investor conferences in September 2026. The company's products, including the FDA-approved Zephyr® Endobronchial Valve, are recognized in global treatment guidelines for severe em…

Scripps taps NBCU sales veteran to lead small and medium business growth and direct response advertising

Scripps taps NBCU sales veteran to lead small and medium business growth and direct response advertising

The E.W. Scripps Company has hired Jen Carfley, formerly of NBCUniversal, as head of small and medium business growth and direct response advertising. Carfley will develop enterprise-wide strategies to connect SMB advertisers with Scripps' premium video inventory across multiple platforms, including local, national, linear, and connected TV. She wi…

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Roivant announced FDA approval of LISRAYA™ (brepocitinib), the first targeted oral therapy for adults with dermatomyositis (DM), a rare autoimmune disease. LISRAYA demonstrated robust efficacy in the largest DM clinical trial to date, improving muscle strength, skin symptoms, physical function, and reducing steroid dependence. The drug is now avail…

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Priovant Therapeutics announced FDA approval of LISRAYA™ (brepocitinib), a first-in-class TYK2/JAK1 inhibitor, for the treatment of adults with dermatomyositis, a rare systemic autoimmune disease. The approval follows positive Phase 3 VALOR trial results demonstrating significant improvements in disease activity and steroid-sparing benefits. LISRAY…

Anthropic Readies IPO Prospectus for Release After Labor Day, Eyes Late September or Early October Listing

Anthropic Readies IPO Prospectus for Release After Labor Day, Eyes Late September or Early October Listing

Anthropic plans to make its IPO prospectus public after Labor Day, with a potential market debut targeted for late September or early October. The firm, which confidentially filed earlier this year, is weighing whether to permit existing shareholders to sell in the offering and is considering lockup periods longer than the typical 180 days. The com…

Buy Reiterated: Opakalim License Boosts Near-Term Upside for Biohaven

Buy Reiterated: Opakalim License Boosts Near-Term Upside for Biohaven

Biohaven shares trade near $15.90 after a pullback; a recently announced Opakalim licensing deal for epilepsy (terms limited) plus multiple 2026 clinical readouts and a still-meaningful cash position support a mid-term, catalyst-driven long. Market cap (~$2.4B), negative EPS (-$4.29), and steep cash burn keep this as a high-risk trade with clearly …

T-Mobile: A Focused Long Trade on the Most Competitive U.S. Carrier

T-Mobile: A Focused Long Trade on the Most Competitive U.S. Carrier

T-Mobile remains the most aggressive and efficient U.S. wireless operator: double-digit service revenue growth, strong free cash flow, a 2.2% yield and an attractive EV/EBITDA multiple. After Q2 volatility and a near-term ex-dividend, the stock offers a defined-risk entry for a mid-term swing trade targeting a re-rating toward prior trading ranges.

Synopsys Q3 Review: Strong Beats, Integration Progress, and the Road Ahead

Synopsys Q3 Review: Strong Beats, Integration Progress, and the Road Ahead

Synopsys reported Q3 FY2026 revenue of $2.477 billion, a 42% year-over-year increase and $37 million above expectations, with non-GAAP EPS of $3.91 versus $3.67 estimated. The company raised full-year guidance, disclosed accelerating Ansys integration progress and synergy targets, and highlighted AI-driven efficiency gains. Despite the beat, shares…

UPDATE -- Canada-Japan Support Advances Xanadu and Mitsubishi Chemical Partnership on Quantum Semiconductor Research

UPDATE -- Canada-Japan Support Advances Xanadu and Mitsubishi Chemical Partnership on Quantum Semiconductor Research

Xanadu Quantum Technologies and Mitsubishi Chemical have entered the next phase of their collaboration to develop quantum computing algorithms aimed at improving extreme ultraviolet (EUV) lithography for semiconductor manufacturing. Supported by innovation programs from Canada and Japan, the partnership focuses on creating a quantum-ready software …